Literature DB >> 29605946

Pharmacist supply of sildenafil: pharmacists' experiences and perceptions on training and tools for supply.

Rhiannon Braund1, Kaushalya Ratnayake2, Katie Tong2, Jackie Song2, Stephen Chai2, Natalie Gauld3.   

Abstract

Background In 2014, New Zealand reclassified sildenafil (for erectile dysfunction) to allow supply by specially trained pharmacists under strict criteria. Objective The study aimed to determine pharmacists' experiences and perspectives on the training for, and supply of sildenafil under this model. Setting New Zealand community pharmacy. Method This qualitative study captured data with a semi-structured interview used with purposively-sampled participants. A maximum variation sample was used to select a wide range of pharmacists working in various pharmacies, including pharmacists who were trained to provide sildenafil and those not trained to supply sildenafil. Consenting pharmacists were interviewed, with interviews audio-recorded and transcribed. Analysis used a framework approach. Main outcome measures Topics explored included: satisfaction and experience of the training; suitability and usability of the screening tools; experiences of the supply process and why some pharmacists chose not to become trained. Results Thirty-five pharmacists were interviewed. Training was seen as uncomplicated and the screening tools provided confidence that key consultation areas were covered. Most consultations reportedly took 15-20 min, some up to 60 min. Pharmacists reported being comfortable with the consultations. Many men requesting supply fell outside of the parameters, resulting in medical referral. This new model of supply was seen as a positive for pharmacists and their patients. Unaccredited pharmacists reported a perceived lack of interest from men, or ability to provide the service as reasons for not seeking accreditation. Conclusion New Zealand's model of pharmacist supply of sildenafil appears workable with some areas for improvement identified.

Entities:  

Keywords:  Community pharmacy services; Erectile dysfunction; New Zealand; Pharmacist’s training; Reclassification; Sildenafil

Mesh:

Substances:

Year:  2018        PMID: 29605946     DOI: 10.1007/s11096-018-0622-z

Source DB:  PubMed          Journal:  Int J Clin Pharm


  32 in total

Review 1.  Qualitative research in health care. Analysing qualitative data.

Authors:  C Pope; S Ziebland; N Mays
Journal:  BMJ       Date:  2000-01-08

Review 2.  Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association.

Authors:  Glenn N Levine; Elaine E Steinke; Faisal G Bakaeen; Biykem Bozkurt; Melvin D Cheitlin; Jamie Beth Conti; Elyse Foster; Tiny Jaarsma; Robert A Kloner; Richard A Lange; Stacy Tessler Lindau; Barry J Maron; Debra K Moser; E Magnus Ohman; Allen D Seftel; William J Stewart
Journal:  Circulation       Date:  2012-01-19       Impact factor: 29.690

3.  Definitions/epidemiology/risk factors for sexual dysfunction.

Authors:  Ronald W Lewis; Kerstin S Fugl-Meyer; Giovanni Corona; Richard D Hayes; Edward O Laumann; Edson D Moreira; Alessandra H Rellini; Taylor Segraves
Journal:  J Sex Med       Date:  2010-04       Impact factor: 3.802

4.  Health-related characteristics and unmet needs of men with erectile dysfunction: a survey in five European countries.

Authors:  Emmanuele A Jannini; Nikoletta Sternbach; Erika Limoncin; Giacomo Ciocca; Giovanni Luca Gravina; Francesca Tripodi; Irene Petruccelli; Sylvia Keijzer; Gina Isherwood; Britta Wiedemann; Chiara Simonelli
Journal:  J Sex Med       Date:  2013-12-09       Impact factor: 3.802

5.  Pharmacist prescribing of hormonal contraceptives: results of the Direct Access study.

Authors:  Jacqueline S Gardner; Leslie Miller; Donald F Downing; Stephanie Le; David Blough; Solmaz Shotorbani
Journal:  J Am Pharm Assoc (2003)       Date:  2008 Mar-Apr

Review 6.  Erectile dysfunction.

Authors:  Rany Shamloul; Hussein Ghanem
Journal:  Lancet       Date:  2012-10-05       Impact factor: 79.321

7.  Male erectile dysfunction: its prevalence in Western australia and associated sociodemographic factors.

Authors:  Kew-Kim Chew; Bronwyn Stuckey; Alexandra Bremner; Carolyn Earle; Konrad Jamrozik
Journal:  J Sex Med       Date:  2007-07-21       Impact factor: 3.802

Review 8.  Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks.

Authors:  G Jackson; S Arver; I Banks; V J Stecher
Journal:  Int J Clin Pract       Date:  2010-01-18       Impact factor: 2.503

9.  The use of a written assessment checklist for the provision of emergency contraception via community pharmacies: a simulated patient study.

Authors:  Carl R Schneider; Sajni Gudka; Limor Fleischer; Rhonda M Clifford
Journal:  Pharm Pract (Granada)       Date:  2013-09-20

10.  Evaluation of the first pharmacist-administered vaccinations in Western Australia: a mixed-methods study.

Authors:  H Laetitia Hattingh; T Fei Sim; R Parsons; P Czarniak; A Vickery; S Ayadurai
Journal:  BMJ Open       Date:  2016-09-20       Impact factor: 2.692

View more
  2 in total

1.  Learning From Consultations Conducted by Community Pharmacists in Northern Ireland for Nonprescription Sildenafil: A Qualitative Study Using the Theoretical Domains Framework.

Authors:  Rineke Gordijn; Martina Teichert; Melianthe P J Nicolai; Henk W Elzevier; Henk-Jan Guchelaar; Carmel M Hughes
Journal:  Sex Med       Date:  2021-10-07       Impact factor: 2.491

Review 2.  Visual Side Effects Linked to Sildenafil Consumption: An Update.

Authors:  Eva Ausó; Violeta Gómez-Vicente; Gema Esquiva
Journal:  Biomedicines       Date:  2021-03-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.